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Abstract
Background: Enteric fever is a major global public health problem and growing international travel
leads to an increase in the risk of contracting infectious diseases that are endemic in the country
of destination.
Case presentation: A 30-year-old Pakistani male was admitted feeling generally unwell with
fever, vertigo, vomiting and headache. Admission blood cultures grew Salmonella ser. Paratyphi A.
The patient was successfully treated with intravenous Amoxicillin/Clavulanic Acid and
Ciprofloxacin.
Conclusion: This case report emphasizes the potent spread of Salmonellae bacilli in a developed
country.
Background
Typhoid fever is the most serious form of enteric fever,
with humans being the sole reservoir of the bacteria.
Based on a recent survey, the global number of typhoid
cases in 2000 exceeded 21,000,000, with more than
200,000 deaths [1]. Enteric fever, that is typhoid and para-
typhoid fevers, is the common name for infections caused
by Salmonella enterica serotypes typhi and paratyphi. Of
the three types of S. paratyphi (A, B, and C), B is the most
common.
Salmonellae are motile, gram-negative, non-spore-form-
ing bacilli and can be differentiated into more than 2000
serotypes (serovars) by their somatic (O) antigens. There
are six serogroups: A, B, C1, C2, D, and E. Although any
Salmonella serotype can produce any of the Salmonella
syndromes each serotype tends to be associated with cer-
tain syndromes much more frequently than others. S.
typhi and S. paratyphi are most likely to cause enteric
fever, as well as the chronic carrier state. There are three
species of Salmonellae that cause paratyphoid: Salmo-
nella paratyphi A, S. paratyphi B (or S. schotmulleri) and
S. paratyphi C (S. hirschfeldii) [2]. As a result of modern
sewage and water treatment facilities, these diseases have
become rare in developed countries but remain a problem
in countries without adequate sanitation and a safe water
supply. Although enteric fever is a major global public
health problem, data on the relative risk of contracting
travel – associated enteric fever in various regions of the
world are scarce. Growing international travel leads to an
increase in the risk of contracting infectious diseases that
are endemic in the country of destination [3].
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other humans and from ingesting contaminated water or
animal food products, most often eggs, poultry, and meat
[2,4,5]. Any food can become contaminated by feces.
After the ingestion of organisms, the likelihood of infec-
tion developing, as well as the severity of infection, is
related to the dose and virulence of the Salmonella strain
and the status of host defense mechanisms. Although any
Salmonella serotype can produce the syndrome of bacter-
emia, S. choleraesuis and S. dublin are most likely to cause
this syndrome.
The asymptomatic intestinal carrier state may result from
inapparent infection or may follow clinical disease. It is
usually self-limited to several weeks to months, with the
incidence of positive stool cultures rapidly decreasing over
time. The syndrome of enteric fever is characterized by
prolonged sustained fever, relative bradycardia, hepat-
osplenomegaly, rose spots, and leucopenia and neutrope-
nia [3]. After an incubation period of 5 to 21 days
(generally 7 to 14 days), fever and malaise develop, often
associated with cough. A small proportion of patients may
have diarrhea during the incubation period. The fever
tends to rise in stepwise fashion over the first few days to
a week and then becomes sustained, usually at 39.4 to
40°C (103 to 104°F) or higher. After 2 weeks of illness,
the severe complications of intestinal hemorrhage or per-
foration may be observed. The illness usually resolves by
the end of the fourth week in an untreated patient.
Relapse may occur in untreated as well as treated patients,
but the illness is milder than the original episode. Rarely,
some of the following complications may occur: pancrea-
titis, cholecystitis, infective endocarditis, pneumonia,
hepatic or splenic abscess, orchitis, or focal infection at
virtually any site [6].
The differential diagnosis of enteric fever is very broad and
depends in part on the area of the world in which the
infection was acquired. The differential diagnosis of Sal-
monella bacteremia includes all acute infectious and non-
infectious causes of fever, including bacteremia caused by
other organisms.
The diagnosis is proved by isolation of the microorganism
from blood or a site of localization. The diagnosis of
enteric fever is best proved by isolation of the microorgan-
ism from blood, stool, or bone marrow. During the first
week of illness, blood cultures are positive in about 90%
of patients, but culture positivity decreases over the next 2
weeks to less than 50% during the third week of illness.
Stool cultures are usually negative during the first week
but by the third week are generally positive. Bone marrow
cultures give the highest yield, with up to 95% being pos-
itive, and should be obtained in suspected cases with neg-
ative blood cultures.
The primary approach to treatment of Salmonella entero-
colitis is fluid and electrolyte replacement, correction of
acid-base disturbances, and in the setting of intestinal
bleeding, blood transfusion. Drugs with antiperistaltic
effects such as loperamide can relieve cramps but can pro-
long the diarrhea. The fluoroquinolones can be used
against Salmonellae [3]. A third-generation cephalosporin
is an alternative. Other agents, such as amoxicillin, chlo-
ramphenicol, ampicillin, azithromycin and trimetho-
prim-sulfamethoxazole, have also been widely used in
severely ill adults. However, many strains of Salmonella
are now resistant to these agents which results in poor
clinical outcomes [6-8]. In the presence of gross bloody
diarrhea, antimicrobial therapy should be withheld until
the possibility of E. coli O157:H7 infection has been elim-
inated because antibiotic therapy may increase the fre-
quency of development of hemolytic-uremic syndrome. If
perforation seems likely, laparotomy should be per-
formed as soon as possible to repair the perforation. Ster-
oid therapy has shown to be beneficial in some patients
with severe enteric fever and coma, delirium, or shock.
Steroids can mask the signs and symptoms of abdominal
perforation and should not be continued for more than
48 hours. Salicylates should be avoided. Relapses of
typhoid fever should be treated with the same antimicro-
bial regimen as the initial attack. In cases of sustained bac-
teremia, the possibility of endovascular infection should
be investigated. For transient bacteremia or bacteremia
without localization, therapy is continued for 7 to 14
days. With localization to bone, aneurysms, heart valves,
and various other sites, antimicrobial therapy should be
given for much longer periods (e.g. 6 weeks). Surgical
drainage, removal of foreign bodies, or resection of an
aneurysm is often necessary to cure localized infection.
Mortality from Salmonella is not uncommon and is most
likely to occur in the very young, the very old, and the
immunocompromised. The mortality rate remains as high
as 30 to 50% in some areas of developing countries. With
perforation, mortality rates of 10 to 30% have been
reported. Up to 3% of patients recovering from S. typhi
infection become chronic fecal carriers.
Case presentation
A 30-year-old Pakistani male was admitted feeling gener-
ally unwell with fever, vertigo, vomiting and headache.
The onset of fever was 3 days after his return from Paki-
stan. His medical history was unremarkable.
His temperature was 41.5°C, blood pressure 135/75 mm
Hg, heart rate 109 beats min-1. Physical examination was
unremarkable.
Analysis of blood showed haemoglobin 13.3 g/DL, white
cell count 3.57 × 109 L-1, neutrophils 5.3 × 109 L-1, Plate-Page 2 of 3
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lets 30 × 109 L-1, Na+ 133 meq/L, SGOT 57 U/L, SGPT 57
U/L, LDH 305 U/L, CPK 252 U/L, C – reactive protein
75,4 mg/L. Urinalysis and urine culture, chest radiogram,
viral and immunological tests, fecal tests, abdominal
ultrasound, thyroid function, the Mantoux test, blood
gases, tumor markers were normal and electrocardiogram
revealed a sinus tachycardia. Treatment was initiated with
intravenous fluid replacement and three sets of blood cul-
tures were taken from different veins. On day 2 of admis-
sion the organism was identified as Salmonella ser.
Paratyphi A, and was resistant to Cefazolin, Cefuroxime
and Aminoglycosides. Antimicrobial therapy was initiated
with Amoxicillin/Clavulanic Acid 1.2 g 8 – hourly (based
on antibiogram) because the patient could not tolerate
oral therapy.
The patient's condition failed to improve and he contin-
ued to spike temperatures of up to 39.5°C. On day 5 of his
admission, his condition was stable and the blood analy-
sis showed SGOT 399 U/L, SGPT 438 U/L, LDH 639 U/L,
CPK 5062 U/L, aPTT 40.45 sec, haemoglobin 13 g/DL,
Platelets 100 × 109 L-1.
On day 7 of admission (5 days after the initiation of anti-
biotic therapy) his temperature was 38.5°C and treatment
was changed with intravenously Ciprofloxacin 500 mg 12
– hourly.
On day 13 of admission the patient became apyrexial, his
clinical condition and the results from the blood analysis
improved. On day 15 of admission he was discharged on
oral ciprofloxacin to continue in the community. No
severe complications of intestinal hemorrhage or perfora-
tion were observed and, even though S. paratyphi is
almost likely to cause chronic carrier state, our patient did
not become chronic carrier.
Conclusion
Our case emphasizes the potent spread of Salmonellae
infection in developed countries from infected immi-
grants. We advocate the need for a high degree of clinical
suspicion, an early diagnosis and prompt institution of
effective antimicrobial therapy to decrease the mortality,
the morbidity and the possibility of outbreak, especially
with a multi-resistant organism.
To our knowledge, this is the first report of enteric fever in
Greece associated with Salmonella ser. Paratyphi A.
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